Agency Information Collection Activities: Submission for OMB Review; Comment Request, 43943-43944 [E8-17354]
Download as PDF
<![CDATA[
43943
Federal Register / Vol. 73, No. 146 / Tuesday, July 29, 2008 / Notices
notify interested persons regarding their
request to speak by August 8, 2008.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Lee L.
Zwanziger at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: July 17, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–17304 Filed 7–28–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources
and Services Administration (HRSA)
publishes abstracts of information
collection requests under review by the
Office of Management and Budget
(OMB), in compliance with the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35). To request a copy of
the clearance requests submitted to
OMB for review, e-mail
paperwork@hrsa.gov or call the HRSA
Reports Clearance Office on (301) 443–
1129.
The following request has been
submitted to the Office of Management
and Budget for review under the
Paperwork Reduction Act of 1995:
Proposed Project: Sickle Cell Disease
Treatment Demonstration Program
(SCDTDP), Health Resources and
Services Administration (HRSA): NEW
In 2004 Congress enacted and the
President signed into law Public Law
108–357, the American Jobs Creation
Act of 2004. Section 712 of Public Law
108–357 authorized a demonstration
program for the prevention and
treatment of Sickle Cell Disease. The
legislation was enacted to (1) create an
optional medical assistance program for
individuals with Sickle Cell Diseases for
treatment and education, genetic
counseling and other services to prevent
mortality and decrease morbidity from
Sickle Cell Disease, and (2) create a
demonstration program, the SCDTDP,
under HRSA. The SCDTDP provides
grants to federally-qualified and
nonprofit health care providers to
establish geographically distributed
regional networks that will work with
comprehensive Sickle Cell Disease
centers and community-based support
organizations to provide coordinated,
comprehensive, culturally competent,
Number of
respondents
Form name
Sickle Cell Disease
clients or caregivers.
Sickle Cell Disease
clients or caregivers.
Sickle Cell Disease
clients or caregivers.
Parents of Sickle Cell
Disease clients.
Sickle Cell Disease
clients age 18 and
younger.
Sickle Cell Disease
clients or caregivers.
Utilization Questionnaire (predemonstration).
Utilization Questionnaire (post
demonstration).
SF–36 Health Survey for adults
over 18 years of age.
PedsQL for parents .....................
Total ....................
jlentini on PROD1PC65 with NOTICES
Type of respondent
Total
responses
Hours per
response
Total burden
hours
400
1
400
.75
300
400
1
400
.50
200
280
2
560
.25
140
120
2
240
.25
60
PedsQL for children and adolescents.
100
2
200
.25
50
The Medical Home Family Index
(Health Care Satisfaction).
400
2
800
.25
200
......................................................
500
........................
2,600
........................
950
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to
VerDate Aug<31>2005
Responses
per
respondent
and family-centered care to families
with Sickle Cell Disease. In fiscal year
2006, HRSA awarded four, 4-year grants
to the Illinois Sickle Cell Association
Network, Alabama Network for Sickle
Cell Care, Access, Prevention, and
Education, Carolina Partnership for
Sickle Cell Treatment Continuum of
Care, and the Cincinnati Sickle Cell
Network.
Under the authorizing legislation, a
National Coordinating Center (NCC) was
established to (1) collect, coordinate,
monitor, and distribute data, best
practices and findings regarding the
activities of the demonstration program,
(2) identify a model protocol for eligible
entities with respect to the prevention
and treatment of Sickle Cell Disease, (3)
identify educational materials regarding
the prevention and treatment of Sickle
Cell Disease, and (4) prepare a final
report on the efficacy of the
demonstration program based on
evaluation findings.
As part of the evaluation, pre and post
utilization and satisfaction data and
quality of life assessments will be
collected from the demonstration clients
during various phases of their
participation. These data will be
collected through medical record
abstractions and self-report using hard
copy questionnaires and submitted to
the NCC for processing and analysis.
The total burden estimate per
participant is shown below:
16:12 Jul 28, 2008
Jkt 214001
the desk officer for HRSA, either by email to OIRA_submission@omb.eop.gov
or by fax to 202–395–6974. Please direct
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
all correspondence to the ‘‘attention of
the desk officer for HRSA.’’
E:\FR\FM\29JYN1.SGM
29JYN1
43944
Federal Register / Vol. 73, No. 146 / Tuesday, July 29, 2008 / Notices
Dated: July 23, 2008.
Alexandra Huttinger,
Director, Division of Policy Review and
Coordination.
[FR Doc. E8–17354 Filed 7–28–08; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
jlentini on PROD1PC65 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Health Risks, Interventions and
Outcomes.
Date: August 5, 2008.
Time: 11 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting)
Contact Person: Michael Micklin, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3136,
MSC 7759, Bethesda, MD 20892, (301) 435–
1258, micklinm@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Microcirculation and Renovascular
Hypertension.
Date: August 21, 2008.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call)
Contact Person: Olga A. Tjurmina, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4030B,
MSC 7814, Bethesda, MD 20892, (301) 451–
1375, ot3d@nih.gov.
VerDate Aug<31>2005
16:12 Jul 28, 2008
Jkt 214001
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Cardiac
Fibrillation and Defibrillation.
Date: September 5, 2008.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call)
Contact Person: Maqsood A. Wani, PhD,
DVM, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2114,
MSC 7814, Bethesda, MD 20892, 301–435–
2270, wanimaqs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, NIH Rapid
Access to Interventional Development
Review.
Date: September 17–18, 2008.
Time: 8 a.m. to 8 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting)
Contact Person: James J. Li, PhD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5148, MSC 7849, Bethesda, MD
20892, 301–435–2417, lijames@csr.nih.gov.
Name of Committee: Oncological Sciences
Integrated Review Group, Developmental
Therapeutics Study Section.
Date: September 18–19, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel, 1515 Rhode Island
Avenue, NW., Washington, DC 20005.
Contact Person: Sharon K. Gubanich, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804,Bethesda, MD 20892, (301) 435–
1767, gubanics@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 21, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–17166 Filed 7–28–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and AlcoholismSpecial
Emphasis Panel; Applications in Response to
PAR–07–157.
Date: August 19, 2008.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Alcohol Abuse
and Alcoholism, 5635 Fishers Lane, Room
3146, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Katrina L Foster, PhD,
Scientific Review Officer, National Inst on
Alcohol Abuse & Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm.
3042,Rockville, MD 20852, 301–443–4032,
Katrina@mali.ruh.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants,
National Institutes of Health, HHS)
Dated: July 18, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–17165 Filed 7–28–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
E:\FR\FM\29JYN1.SGM
29JYN1
]]>Agencies
[Federal Register Volume 73, Number 146 (Tuesday, July 29, 2008)]
[Notices]
[Pages 43943-43944]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17354]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources and Services Administration
(HRSA) publishes abstracts of information collection requests under
review by the Office of Management and Budget (OMB), in compliance with
the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request
a copy of the clearance requests submitted to OMB for review, e-mail
paperwork@hrsa.gov or call the HRSA Reports Clearance Office on (301)
443-1129.
The following request has been submitted to the Office of
Management and Budget for review under the Paperwork Reduction Act of
1995:
Proposed Project: Sickle Cell Disease Treatment Demonstration Program
(SCDTDP), Health Resources and Services Administration (HRSA): NEW
In 2004 Congress enacted and the President signed into law Public
Law 108-357, the American Jobs Creation Act of 2004. Section 712 of
Public Law 108-357 authorized a demonstration program for the
prevention and treatment of Sickle Cell Disease. The legislation was
enacted to (1) create an optional medical assistance program for
individuals with Sickle Cell Diseases for treatment and education,
genetic counseling and other services to prevent mortality and decrease
morbidity from Sickle Cell Disease, and (2) create a demonstration
program, the SCDTDP, under HRSA. The SCDTDP provides grants to
federally-qualified and nonprofit health care providers to establish
geographically distributed regional networks that will work with
comprehensive Sickle Cell Disease centers and community-based support
organizations to provide coordinated, comprehensive, culturally
competent, and family-centered care to families with Sickle Cell
Disease. In fiscal year 2006, HRSA awarded four, 4-year grants to the
Illinois Sickle Cell Association Network, Alabama Network for Sickle
Cell Care, Access, Prevention, and Education, Carolina Partnership for
Sickle Cell Treatment Continuum of Care, and the Cincinnati Sickle Cell
Network.
Under the authorizing legislation, a National Coordinating Center
(NCC) was established to (1) collect, coordinate, monitor, and
distribute data, best practices and findings regarding the activities
of the demonstration program, (2) identify a model protocol for
eligible entities with respect to the prevention and treatment of
Sickle Cell Disease, (3) identify educational materials regarding the
prevention and treatment of Sickle Cell Disease, and (4) prepare a
final report on the efficacy of the demonstration program based on
evaluation findings.
As part of the evaluation, pre and post utilization and
satisfaction data and quality of life assessments will be collected
from the demonstration clients during various phases of their
participation. These data will be collected through medical record
abstractions and self-report using hard copy questionnaires and
submitted to the NCC for processing and analysis.
The total burden estimate per participant is shown below:
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Responses per Total Hours per Total burden
Type of respondent Form name respondents respondent responses response hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Sickle Cell Disease clients or caregivers. Utilization Questionnaire 400 1 400 .75 300
(pre-demonstration).
Sickle Cell Disease clients or caregivers. Utilization Questionnaire 400 1 400 .50 200
(post demonstration).
Sickle Cell Disease clients or caregivers. SF-36 Health Survey for 280 2 560 .25 140
adults over 18 years of age.
Parents of Sickle Cell Disease clients.... PedsQL for parents.......... 120 2 240 .25 60
Sickle Cell Disease clients age 18 and PedsQL for children and 100 2 200 .25 50
younger. adolescents.
Sickle Cell Disease clients or caregivers. The Medical Home Family 400 2 800 .25 200
Index (Health Care
Satisfaction).
-------------------------------------------------------------------------------
Total................................. ............................ 500 .............. 2,600 .............. 950
--------------------------------------------------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent within 30 days of this notice to
the desk officer for HRSA, either by e-mail to OIRA_
submission@omb.eop.gov or by fax to 202-395-6974. Please direct all
correspondence to the ``attention of the desk officer for HRSA.''
[[Page 43944]]
Dated: July 23, 2008.
Alexandra Huttinger,
Director, Division of Policy Review and Coordination.
[FR Doc. E8-17354 Filed 7-28-08; 8:45 am]
BILLING CODE 4165-15-P
